Fig 2: Correlation between KIF2C expression and immunotherapy in breast cancer. (A) Cytolytic activity scores between high and low KIF2C expression group. (B) The expression of the immune checkpoint molecules between high and low KIF2C group. (C) Heatmap for predicting effect on anti-PD-1 and anti-CTLA4-R therapy. (D) TIDE immunotherapy prediction analyses between high and low KIF2C group. *P < 0 0.05, **P < 0 0.01, ***P < 0.001, ****P < 0.0001

Fig 3: Upregulation of KIF2C expression in breast cancer. (A) The expression of KIF2C in paired tumor and normal tissue samples in TIMER database. (B) The expression of KIF2C between breast cancer and adjacent normal tissue samples in the TCGA database. (C) The expression of KIF2C between breast cancer and adjacent normal tissue samples on the GSE36295 dataset. (D) Representative images of immunohistochemical staining of KIF2C in breast cancer and paired adjacent normal tissues. The expression of KIF2C is upregulated in breast cancer tissues, as compared to their paired non-tumor tissues. (E) Box plot showing H-scores on tissue array for both tumor tissues and paired non-tumor tissues. *P < 0 0.05, **P < 0 0.01, ***P < 0.001, ****P < 0.0001

Fig 4: Construction and evaluation of nomogram for OS prediction of patients with breast cancer. (A) Nomograms predicting 1-year, 3-year and 5-year survival of breast cancer patients based on age, TMN stage, ER and KIF2C expression. (B) Calibration curve of nomogram. (C) ROC curve of nomogram. (D) Decision curve analysis (DCA) curve for the clinical utilize of nomogram

Fig 5: Correlation between the expression of KIF2C and clinical pathological characteristics of patients with breast cancer: Age (A), TMN stage (B), T status (C), N status (D), molecular subtypes (E). (F-H) The effects of different expression levels of KIF2C on the OS of patients with breast cancer using TCGA database (F), GSE42568 datasets (G) and GSE20685 datasets (H). *P < 0 0.05, **P < 0 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant